Drug profile

The FDA adverse-event record for Feline Calicivirus, Strain F-9, Passage 7, Lot A; Feline Chlamydia Psittaci, Str

133 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Feline Calicivirus, Strain F-9, Passage 7, Lot A; Feline Chlamydia Psittaci, Str. See the species affected, top reactions, and outcomes below.

133
adverse-event reports
18.8%
death-coded share
Cat
most-reported species
75
Lethargy (see also Central nervous system depression in 'Neurological') - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
133
Total Reports
25
Deaths Reported
18.8%
Death Rate

Active Ingredients

Feline Calicivirus, Strain F-9, Passage 7, Lot A; Feline Chlamydia Psittaci, Str

Administration Routes

Subcutaneous

Species Affected

Cat 133

Most Affected Breeds

Domestic Shorthair 88
Domestic Longhair 9
Siamese 7
Domestic Mediumhair 7
Persian 6
Ragdoll 4
Maine Coon 3
Bengal 2
Cat (other) 2
Norwegian Forest 1

Most Reported Reactions

Lethargy (see also Central nervous system depression in 'Neurological') 75
Anorexia 57
Fever 51
Weight loss 28
Other abnormal test result NOS 25
Vomiting 20
Dehydration 19
Abnormal radiograph finding 17
Febrile 15
Death by euthanasia 15
Anaemia NOS 15
Decreased appetite 15

Outcome Breakdown

Ongoing
69 (50.7%)
Recovered/Normal
37 (27.2%)
Euthanized
15 (11.0%)
Died
10 (7.4%)
Outcome Unknown
5 (3.7%)

Feline Calicivirus, Strain F-9, Passage 7, Lot A; Feline Chlamydia Psittaci, Str Adverse Event Insights

133 reports name Feline Calicivirus, Strain F-9, Passage 7, Lot A; Feline Chlamydia Psittaci, Str; 25 recorded a death outcome (18.8% of reported events, not a population-level mortality rate). Active ingredient: Feline Calicivirus, Strain F-9, Passage 7, Lot A; Feline Chlamydia Psittaci, Str. Administration route: Subcutaneous.

By species: Cat (133 reports). By breed: Domestic Shorthair (88), Domestic Longhair (9), Siamese (7).

Leading clinical signs: Lethargy (see also Central nervous system depression in 'Neurological') (75), Anorexia (57), Fever (51), Weight loss (28). Outcome, 136 coded reports: Ongoing leads at 50.7%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.